Quarterly ResultMay 15, 2026, 08:07 AM
MiNK Therapeutics Initiates Phase 2 Trial for agenT-797; Q1 Net Loss $2.7M
AI Summary
MiNK Therapeutics reported its first quarter 2026 financial results and provided a corporate update, highlighting the initiation of a randomized Phase 2 clinical trial for agenT-797 in severe acute lung injury, with preliminary data expected in the second half of 2026. The company also announced a non-dilutive collaboration with C-Further for pediatric cancers, providing up to $1.1 million in funding. Financially, MiNK ended the quarter with $9.5 million in cash, repaid a $5.2 million convertible note, and raised $3.0 million through at-the-market sales, reporting a net loss of $2.7 million.
Key Highlights
- Initiated randomized Phase 2 trial for agenT-797 in severe acute lung injury.
- Preliminary Phase 2 data for agenT-797 expected in the second half of 2026.
- Secured non-dilutive collaboration with C-Further, providing up to $1.1M funding.
- Cash and cash equivalents were approximately $9.5M as of March 31, 2026.
- Repaid approximately $5.2M associated with the Agenus convertible note.
- Raised approximately $3.0M through at-the-market sales during Q1 2026.
- Reported Q1 2026 net loss of approximately $2.7M, or $0.57 per share.
- New clinical data to be presented at the ATS conference on May 20, 2026.
Price Impact
More from INKT